SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-002301
Filing Date
2024-01-05
Accepted
2024-01-05 08:54:09
Documents
1
Period of Report
2023-08-31

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 7731
  Complete submission text file 0000950170-24-002301.txt   9198
Mailing Address C/O FUSION PHARMACEUTICALS INC. 2 INTERNATIONAL PLACE SUITE 2310 BOSTON MA 02110
Business Address
Leamon Christopher P (Reporting) CIK: 0001509415 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39344 | Film No.: 24514544

Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Issuer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)